Home › Biomarkers › NTRK
NTRK testing: what it means for you
Waiting on test results can feel like one more hard thing, for you and the people who love you. Here's what the NTRK test looks for and how it can help your care team pick the treatment most likely to work for you.
ℹ️ General information to help you and your loved ones talk with your care team, not medical advice. Read our disclaimer.
Matters most in: Lung cancer, Colorectal cancer, Breast cancer
The quick guide
What the test looks for: Fusions in the NTRK1, NTRK2 or NTRK3 genes. Rare in common cancers (under 1%) but can show up in almost any tumor type.
Why it matters
NTRK fusions can be treated with 'tumor-agnostic' pills that work no matter where the cancer started.
Treatments it can point to
- TRK pills such as larotrectinib, entrectinib or repotrectinib
Only your care team can say which treatment fits you. Drug approvals depend on cancer type, stage and prior treatment.
Tissue vs. blood testing
Tissue, ideally with an RNA-based panel.
Most tests use a piece of tumor tissue from a biopsy or surgery. Some can also use a blood sample (a 'liquid biopsy') that looks for tumor DNA floating in the blood. Blood tests are easier and faster, but they can miss a change that a tissue test would find, so a negative blood test is often followed by a tissue test.
❓ Questions you and your loved ones can ask
- Did my testing look for NTRK fusions?
- When will my results be back, and will treatment wait for them?
- Will my insurance cover this test?
Written by the Cancer Side Effects Guide team from FDA labels and leading cancer centers. Not medical advice. · Last updated: October 15, 2026 · How we write
Sources
- NCI: Tumor-agnostic drugs (Targeted Therapy)
- Memorial Sloan Kettering: Targeted Therapy & Precision Oncology
- NCI: Biomarker Testing for Cancer Treatment
- FDA: List of Cleared or Approved Companion Diagnostic Devices
- NCCN Guidelines for Patients: Early and Locally Advanced Non-Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Colon Cancer, 2026
- NCCN Guidelines for Patients: Rectal Cancer, 2026
- NCCN Guidelines for Patients: Invasive Breast Cancer, 2026
- NCCN Guidelines for Patients: Ductal Carcinoma in Situ (Stage 0 Breast Cancer), 2026
- NCCN Guidelines for Patients: Metastatic Breast Cancer, 2026
- NCCN Guidelines for Patients: Inflammatory Breast Cancer, 2026